


Otamixaban

Cat. No.:	HY-70035		
CAS No.:	193153-04-7		
Molecular Formula:	C ₂₅ H ₂₆ N ₄ O ₄		
Molecular Weight:	446.5		
Target:	Factor Xa		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (111.98 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.2396 mL	11.1982 mL	22.3964 mL
	5 mM	0.4479 mL	2.2396 mL	4.4793 mL
	10 mM	0.2240 mL	1.1198 mL	2.2396 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.75 mg/mL (6.16 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.75 mg/mL (6.16 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.75 mg/mL (6.16 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Otamixaban(FXV673) is a potent (K_i = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. IC₅₀ value: Target: Factor Xa Otamixaban is a potent (K_i = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. In vivo experiments have demonstrated that Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis. In addition, recent clinical findings indicate that Otamixaban is efficacious, safe and well tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome. This review article chronicles the discovery and pre-clinical data surrounding the fXa inhibitor Otamixaban as well as the recent clinical findings in humans.

CUSTOMER VALIDATION

- Elife. 2022 Mar 23;11:e77444.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Eikelboom JW, Weitz JI. Otamixaban in acute coronary syndromes. *Lancet*. 2009 Sep 5;374(9692):762-4. Epub 2009 Aug 28.
- [2]. Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. *Lancet*. 2009 Sep 5;374(9692):787-95. Epub 2009 Aug 28
- [3]. Guertin KR, Choi YM. The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. *Curr Med Chem*. 2007;14(23):2471-81.
- [4]. Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. *Circulation*. 2007
- [5]. Guertin, Kevin R.; Choi, Yong-Mi. The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development. *Current Medicinal Chemistry* (2007), 14(23), 2471-2481.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA